Erythropoietin therapy, also known as EPO therapy, is a type of medical treatment that uses a man-made form of erythropoietin (EPO) to increase red blood cell production and treat anemia.
🛒 How to order this item?
100% Genuine Products, Guaranteed
Safe & Secure Payments, Always
Fast, Secure & Efficient Delivery
Proper Packaging
Show More
Recombinant Erythropoietin (rEPO):
Darbepoetin Alfa (DA):
Erythropoietin Therapy (EPO Therapy):
EPO therapy utilizes synthetic forms of erythropoietin to boost red blood cell production, treating anemia.
EPO therapy should only be administered under the supervision of a healthcare professional, and patients should be monitored closely for adverse effects.
It is not known whether it is safe to consume alcohol with Epoetin 4000 IU Injection Please consult your doctor.
Epoetin 4000 IU Injection may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
Epoetin 4000 IU Injection is probably safe to use during breastfeeding. Limited human data suggests that the drug does not represent any significant risk to the baby.
Epoetin 4000 IU Injection may cause side effects which could affect your ability to drive.
Epoetin 4000 IU Injection is safe to use in patients with kidney disease. No dose adjustment of Epoetin 4000 IU Injection is recommended. Regular monitoring of kidney function tests is advised while the patient is taking this medicine.
Epoetin 4000 IU Injection should be used with caution in patients with liver disease. A dose adjustment of Epoetin 4000 may be needed. Please consult your doctor.
Erythropoietin is usually given in the clinical/hospital setting under the supervision of a qualified healthcare professional.
Epoetin 4000 IU Injection is an erythropoiesis-stimulating agent (ESA). It works by stimulating the bone marrow (soft tissue inside the bones which produces red blood cells) to produce more red blood cells.
Erythropoietin and epoetin alfa play crucial roles in regulating erythrocyte differentiation and maintaining the appropriate level of circulating erythrocyte mass in the body. When administered, they stimulate the production of red blood cells (erythropoiesis) and subsequently increase the levels of reticulocytes, red blood cells, hemoglobin, and hematocrit.
The response to erythropoietin or epoetin alfa administration typically begins with an increase in the reticulocyte count within 10 days of initiation. This is followed by increases in the red blood cell count, hemoglobin, and hematocrit, which usually occur within 2 to 6 weeks.
The rate of hemoglobin increase may vary depending on the dose administered. In patients undergoing hemodialysis, it has been observed that doses exceeding 300 Units/kg administered three times weekly do not result in a greater biological response.
Epoetin alfa is particularly used to address erythropoietin deficiency in various pathological and clinical conditions where the normal production of erythropoietin is compromised. For example, in anemic patients with chronic renal failure, epoetin alfa administration stimulates erythropoiesis, leading to increases in reticulocyte count, red blood cell count, hemoglobin, and hematocrit, typically within 2 to 6 weeks.
Epoetin alfa has also been found effective in increasing hematocrit levels in HIV-infected patients receiving zidovudine treatment and in anemic cancer patients undergoing chemotherapy.
Chronic Kidney Disease-Associated Anemia (Patient not on dialysis):
Chronic Kidney Disease-Associated Anemia (Patient on dialysis):
Zidovudine-Related Anemia:
Chemotherapy-Related Anemia:
Preparation for Surgery With High Risk of Blood Loss:
Chronic Kidney Disease-Associated Anemia:
1 month: 50 units/kg IV/SC 3 times weekly initially
Prematurity-Related Anemia:
Zidovudine-Related Anemia (8 months-17 years):
Chemotherapy-Related Anemia (5-18 years):
Before receiving Epoetin 4000 IU Injection, it is important to inform your doctor about any medications you are currently taking, including:
Erythropoietin should not be used in certain medical conditions due to potential risks and adverse effects:
In the hospital, pre-filled syringes are stored unopened in a refrigerator between 2 and 8 ℃. If you are using this medicine at home, the pre-filled syringe must be stored in your refrigerator. Do not store it in the freezer. Allow the pre-filled syringe to reach room temperature before using it. This usually takes between 15 and 30 minutes. Recombinant Human Erythropoietin Alfa pre-filled syringes that are being used or about to be used can be kept at room temperature (not above 25°C) for a maximum single period of 7 days. Keep these pre-filled syringes away from children and protected from light.
Disclaimer:
ePharma sole intention is to ensure that its consumers get proper
information as musch as possible. Although we do not guarantee the
accuracy and the completeness of the information that provided and
here information is for informational purposes only.
The information contained herein should NOT be used as a substitute
for the advice of a qualified physician. This may not cover
everything about particular health conditions,
lab tests, medicines, all possible side effects, drug interactions,
warnings, alerts, etc. Please consult your healthcare professional
and discuss all your queries related to any disease or medicine. We
intend to support, not replace, the doctor-patient relationship.